Benchmark Capital Management Co. V, L.L.C. 4

Accession 0001209191-20-006392

CIK 0001404123other

View on SEC.gov Company Profile

Filed

Feb 3, 7:00 PM ET

Accepted

Feb 4, 4:38 PM ET

Size

36.2 KB

Accession

0001209191-20-006392

Insider Transaction Report

Form 4

Period: 2020-02-04

1Life Healthcare IncONEM

Benchmark Capital Management Co. V, L.L.C.

10% Owner

Transactions

Conversion
Common Stock
2020-02-04+679,393→ 13,398,383 total(indirect: See Footnote)
Conversion
Common Stock
2020-02-04+220,217→ 13,618,600 total(indirect: See Footnote)
Conversion
Common Stock
2020-02-04+3,046,168→ 12,718,990 total(indirect: See Footnote)
Conversion
Series B Preferred Stock
2020-02-04−5,749,630→ 0 total(indirect: See Footnote)
→ Common Stock (5,749,630 underlying)
Conversion
Series D Preferred Stock
2020-02-04−3,046,168→ 0 total(indirect: See Footnote)
→ Common Stock (3,046,168 underlying)
Conversion
Series E Preferred Stock
2020-02-04−679,393→ 0 total(indirect: See Footnote)
→ Common Stock (679,393 underlying)
Conversion
Common Stock
2020-02-04+5,749,630→ 5,936,630 total(indirect: See Footnote)
Conversion
Series C Preferred Stock
2020-02-04−3,736,192→ 0 total(indirect: See Footnote)
→ Common Stock (3,736,192 underlying)
Conversion
Common Stock
2020-02-04+3,736,192→ 9,672,822 total(indirect: See Footnote)
Conversion
Series G Preferred Stock
2020-02-04−220,217→ 0 total(indirect: See Footnote)
→ Common Stock (220,217 underlying)
Conversion
Warrant (Right to Buy)
2020-02-04−11,010→ 0 total(indirect: See Footnote)
Exercise: $6.59Exp: 2020-10-03→ Series G Preferred Stock (11,010 underlying)
Conversion
Warrant (Right to Buy)
2020-02-04+11,010→ 11,010 total(indirect: See Footnote)
Exercise: $6.59Exp: 2020-10-03→ Common Stock (11,010 underlying)

Benchmark Capital Partners V L P

10% Owner

Transactions

Conversion
Common Stock
2020-02-04+3,736,192→ 9,672,822 total(indirect: See Footnote)
Conversion
Common Stock
2020-02-04+3,046,168→ 12,718,990 total(indirect: See Footnote)
Conversion
Series E Preferred Stock
2020-02-04−679,393→ 0 total(indirect: See Footnote)
→ Common Stock (679,393 underlying)
Conversion
Warrant (Right to Buy)
2020-02-04−11,010→ 0 total(indirect: See Footnote)
Exercise: $6.59Exp: 2020-10-03→ Series G Preferred Stock (11,010 underlying)
Conversion
Common Stock
2020-02-04+5,749,630→ 5,936,630 total(indirect: See Footnote)
Conversion
Common Stock
2020-02-04+679,393→ 13,398,383 total(indirect: See Footnote)
Conversion
Series B Preferred Stock
2020-02-04−5,749,630→ 0 total(indirect: See Footnote)
→ Common Stock (5,749,630 underlying)
Conversion
Series C Preferred Stock
2020-02-04−3,736,192→ 0 total(indirect: See Footnote)
→ Common Stock (3,736,192 underlying)
Conversion
Series G Preferred Stock
2020-02-04−220,217→ 0 total(indirect: See Footnote)
→ Common Stock (220,217 underlying)
Conversion
Warrant (Right to Buy)
2020-02-04+11,010→ 11,010 total(indirect: See Footnote)
Exercise: $6.59Exp: 2020-10-03→ Common Stock (11,010 underlying)
Conversion
Common Stock
2020-02-04+220,217→ 13,618,600 total(indirect: See Footnote)
Conversion
Series D Preferred Stock
2020-02-04−3,046,168→ 0 total(indirect: See Footnote)
→ Common Stock (3,046,168 underlying)

BENCHMARK FOUNDERS FUND V LP

10% Owner

Transactions

Conversion
Series D Preferred Stock
2020-02-04−3,046,168→ 0 total(indirect: See Footnote)
→ Common Stock (3,046,168 underlying)
Conversion
Warrant (Right to Buy)
2020-02-04−11,010→ 0 total(indirect: See Footnote)
Exercise: $6.59Exp: 2020-10-03→ Series G Preferred Stock (11,010 underlying)
Conversion
Series E Preferred Stock
2020-02-04−679,393→ 0 total(indirect: See Footnote)
→ Common Stock (679,393 underlying)
Conversion
Common Stock
2020-02-04+220,217→ 13,618,600 total(indirect: See Footnote)
Conversion
Common Stock
2020-02-04+5,749,630→ 5,936,630 total(indirect: See Footnote)
Conversion
Series G Preferred Stock
2020-02-04−220,217→ 0 total(indirect: See Footnote)
→ Common Stock (220,217 underlying)
Conversion
Warrant (Right to Buy)
2020-02-04+11,010→ 11,010 total(indirect: See Footnote)
Exercise: $6.59Exp: 2020-10-03→ Common Stock (11,010 underlying)
Conversion
Common Stock
2020-02-04+679,393→ 13,398,383 total(indirect: See Footnote)
Conversion
Series C Preferred Stock
2020-02-04−3,736,192→ 0 total(indirect: See Footnote)
→ Common Stock (3,736,192 underlying)
Conversion
Common Stock
2020-02-04+3,736,192→ 9,672,822 total(indirect: See Footnote)
Conversion
Common Stock
2020-02-04+3,046,168→ 12,718,990 total(indirect: See Footnote)
Conversion
Series B Preferred Stock
2020-02-04−5,749,630→ 0 total(indirect: See Footnote)
→ Common Stock (5,749,630 underlying)

Benchmark Founders Fund V-A LP

10% Owner

Transactions

Conversion
Common Stock
2020-02-04+220,217→ 13,618,600 total(indirect: See Footnote)
Conversion
Common Stock
2020-02-04+5,749,630→ 5,936,630 total(indirect: See Footnote)
Conversion
Common Stock
2020-02-04+3,046,168→ 12,718,990 total(indirect: See Footnote)
Conversion
Series E Preferred Stock
2020-02-04−679,393→ 0 total(indirect: See Footnote)
→ Common Stock (679,393 underlying)
Conversion
Common Stock
2020-02-04+3,736,192→ 9,672,822 total(indirect: See Footnote)
Conversion
Common Stock
2020-02-04+679,393→ 13,398,383 total(indirect: See Footnote)
Conversion
Series B Preferred Stock
2020-02-04−5,749,630→ 0 total(indirect: See Footnote)
→ Common Stock (5,749,630 underlying)
Conversion
Series G Preferred Stock
2020-02-04−220,217→ 0 total(indirect: See Footnote)
→ Common Stock (220,217 underlying)
Conversion
Warrant (Right to Buy)
2020-02-04+11,010→ 11,010 total(indirect: See Footnote)
Exercise: $6.59Exp: 2020-10-03→ Common Stock (11,010 underlying)
Conversion
Series C Preferred Stock
2020-02-04−3,736,192→ 0 total(indirect: See Footnote)
→ Common Stock (3,736,192 underlying)
Conversion
Series D Preferred Stock
2020-02-04−3,046,168→ 0 total(indirect: See Footnote)
→ Common Stock (3,046,168 underlying)
Conversion
Warrant (Right to Buy)
2020-02-04−11,010→ 0 total(indirect: See Footnote)
Exercise: $6.59Exp: 2020-10-03→ Series G Preferred Stock (11,010 underlying)

Benchmark Founders Fund V-B LP

10% Owner

Transactions

Conversion
Common Stock
2020-02-04+3,736,192→ 9,672,822 total(indirect: See Footnote)
Conversion
Common Stock
2020-02-04+220,217→ 13,618,600 total(indirect: See Footnote)
Conversion
Series D Preferred Stock
2020-02-04−3,046,168→ 0 total(indirect: See Footnote)
→ Common Stock (3,046,168 underlying)
Conversion
Series E Preferred Stock
2020-02-04−679,393→ 0 total(indirect: See Footnote)
→ Common Stock (679,393 underlying)
Conversion
Series C Preferred Stock
2020-02-04−3,736,192→ 0 total(indirect: See Footnote)
→ Common Stock (3,736,192 underlying)
Conversion
Series G Preferred Stock
2020-02-04−220,217→ 0 total(indirect: See Footnote)
→ Common Stock (220,217 underlying)
Conversion
Warrant (Right to Buy)
2020-02-04+11,010→ 11,010 total(indirect: See Footnote)
Exercise: $6.59Exp: 2020-10-03→ Common Stock (11,010 underlying)
Conversion
Series B Preferred Stock
2020-02-04−5,749,630→ 0 total(indirect: See Footnote)
→ Common Stock (5,749,630 underlying)
Conversion
Common Stock
2020-02-04+3,046,168→ 12,718,990 total(indirect: See Footnote)
Conversion
Common Stock
2020-02-04+5,749,630→ 5,936,630 total(indirect: See Footnote)
Conversion
Common Stock
2020-02-04+679,393→ 13,398,383 total(indirect: See Footnote)
Conversion
Warrant (Right to Buy)
2020-02-04−11,010→ 0 total(indirect: See Footnote)
Exercise: $6.59Exp: 2020-10-03→ Series G Preferred Stock (11,010 underlying)

Footnotes (3)

[F1]Each share of Issuer's Preferred Stock automatically converted into an equal number of shares of Issuer's Common Stock upon the closing of the Issuer's initial public offering and has no expiration date.
[F2]Securities held by Benchmark Capital Partners V, L.P. ("BCP V"), as nominee for BCP V, Benchmark Founders' Fund V, L.P. ("BFF V"), Benchmark Founders' Fund V-A, L.P. ("BFF V-A"), Benchmark Founders' Fund V-B, L.P. ("BFF V-B"), and related individuals. Benchmark Capital Management Co. V, L.L.C. ("BCMC V"), the general partner of BCP V, BFF V, BFF V-A and BFF V-B, may be deemed to have sole voting and dispositive power over the securities. Bruce W. Dunlevie, a member of the Issuer's board of directors, Alexandre Balkanski, Peter H. Fenton, J. William Gurley, Kevin R. Harvey, Robert C. Kagle, Mitchell H. Lasky and Steven M. Spurlock are the managing members of BCMC V, and each of them may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims the existence of a "group" and disclaims beneficial ownership of the securities, except to the extent of such person or entity's pecuniary interest in such securities.
[F3]Shares subject to the warrant are immediately exercisable.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

1Life Healthcare Inc

CIK 0001404123

→

Entity typeother

IncorporatedDE

Related Parties

filerCIK 0001511025

Filing Metadata

Form type: 4
Filed: Feb 3, 7:00 PM ET
Accepted: Feb 4, 4:38 PM ET
Size: 36.2 KB

View on SEC.gov